NCT07907575Not yet recruiting
The Role of ERBT Plus Adjuvant Intravesical Induction and Maintenance Chemotherapy for Intermediate-Risk NMIBC
A Randomised Trial Investigating The Role of En Bloc Resection of Bladder Tumour Plus Adjuvant Intravesical Induction and Maintenance Chemotherapy for Intermediate-Risk Non-Muscle-Invasive Bladder Cancer
Source: ClinicalTrials.gov · Last updated 30 Oct 2026
Brief summary (registry, in English)
This is a prospective, multi-centre randomised trial comparing between ERBT plus 1-year of Ad-MMC, versus ERBT alone, in treating intermediate-risk NMIBC.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 440 (estimated)
- First submitted
- 25 Oct 2026
- Start date
- 1 Jan 2027
- Primary completion date
- 31 Dec 2029
- Lead sponsor
- Chinese University of Hong Kong
- Diseases
- Bladder cancer
- NCT number
- NCT07907575
What you commit to
- Study type: Interventional
- Planned participants: 440
- From 1 Jan 2027 to the primary completion date, 31 Dec 2029
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Any prior use of intravesical induction and/or maintenance chemotherapy instillations
- Any prior use of intravesical BCG therapy
- Presence or prior history of upper urinary tract malignancy
- Presence of clinically significant cardiovascular disease (History of acute myocardial infarction, presence of uncontrolled angina within 3 months before screening, New York Heart Association Class III or IV congestive heart failure, presence of ventricular arrhythmias, or presence of second-degree or third-degree heart block) (20)
Other illness
- Presence of GOLD Stage III or IV chronic obstructive pulmonary disease (21)
- Presence of other active malignancy
Other
- ECOG performance status ≥ 2 (Ambulatory and capable of all self-care but unable to carry our any work activities)
- Pregnancy
Who the study is looking for
- Age ≥ 18 years old with informed consent
- ERBT was successfully performed with clear resection margins
- Histologically confirmed intermediate-risk NMIBC
- Patients who are ineligible or refused to undergo intravesical BCG therapy
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Prince of Wales Hospital Coordinator of this site? Confirm its status | Hong Kong | Hong Kong SAR China | Unknown status |
| Prince of Wales Hospital Coordinator of this site? Confirm its status | Shatin | Hong Kong SAR China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.